PDGFRA and gastrointestinal stromal tumor: Ripretinib, a novel switch-control TKI designed to broadly inhibit KIT and PDGFRA kinase signaling through a dual mechanism of action [14], is approved for the treatment of adult patients with advanced GIST who have received prior treatment with three or more TKIs, including imatinib, based on the results of the phase 3 INVICTUS study (NCT03353753) [15, 16].